Skip to main content
. Author manuscript; available in PMC: 2015 Jul 27.
Published in final edited form as: Cancer Clin Oncol. 2012 Nov;1(2):49–80. doi: 10.5539/cco.v1n2p49

Figure 7.

Figure 7

Collective cytotoxic anti-neoplastic potency of epirubicin-(C3-amide)-[anti-HER2/neu] synthesized with an epirubicin UV-photoactivated intermediate when applied in combination with mebendazole or griseofulvin tubulin/microtubule inhibitors. Legend: (◆) epirubicin-(C3-amide)-[anti-HER2/neu]; (▲) epirubicin-(C3-amide)-[anti-HER2/neu] in combination with griseofulvin (15 μM fixed concentration); and (■) epirubicin-(C3-amide)-[anti-HER2/neu] in combination with mebendazole (0.35 μM fixed concentration). Mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with the covalent epirubicin-immunochemotherapeutic in combination with the tubulin/microtubule inhibitors for 72-hours and cytotoxicity measured as a function of MTT cell vitality stain intensity (absorbance at 570 nm) relative to matched negative reference controls.